Vinglyn and Vinglyn M will be marketed by Zydus Healthcare Ltd, it added.
Zydus Cadila Managing Director Sharvil Patel said, "Fortifying our fight against diabetes, our aim is to make therapies affordable and accessible to patients from across sections of society."
With Vinglyn, Zydus Cadila believes that it has once again been able to offer this. The access to one of the most affordable gliptin therapies will help a large number of patients suffering from type-2 diabetes, in India, he added.
With a patient population of almost 77 million diabetics in India, access to affordable therapy is vital for the effective management of the disease, the statement said.
The drug belongs to the class of oral anti-diabetic agents, known as DPP4 inhibitors, which have shown promise in achieving glycaemic control without deterioration in beta cell function and are one of the recent advancements in diabetes care and management, the statement said.
Another drug firm Panacea Biotec on Tuesday had said it had launched its VilACT brand tablets available in four formulations, for treatment of type-2 diabetes in India.
The company had also said its brand will be an affordable and high-quality medicine.
According to the AIOCD MAT October 2019 data, the total market size of this molecule and its combination is Rs 969 crore and is growing at the rate of 4 per cent, Panacea Biotec had said.
Shares of Cadila Healthcare, the listed entity of the Zydus group closed at Rs 262.25 per scrip on the BSE, up 0.50 per cent from its previous close.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.